Hippocratic AI, a developer of patient-facing generative AI agents for healthcare just secured $126 million in a Series C funding round, pushing its valuation to $3.5 billion. Led by Avenir Growth, the latest round brings the company’s total capital raised to $404 million.
Since its founding in 2023, Hippocratic AI has emerged as a major player in healthcare AI, focusing on safety and trust alongside technological innovation. The company’s AI agents assist with appointment scheduling, patient intake history, social determinants of health screening, chronic disease management, and post-discharge outreach.
In addition to Avenir Growth, investors participating in the round included CapitalG (Google’s growth fund), General Catalyst, Andreessen Horowitz, Kleiner Perkins, Universal Health Services, and Cincinnati Children’s Hospital Medical Center.
These investors are attracted by Hippocratic AI’s blend of clinical expertise and advanced AI research, rooted in collaboration with institutions such as Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA.
“Their growth is a testament to the demand for scalable AI solutions addressing these critical challenges,” said Julie Yoo, General Partner at Andreessen Horowitz who highlighted the company’s rapid growth amid the labor and patient access crisis facing global healthcare.
Scaling With a Focus on Safety
Hippocratic AI places safety at the heart of its technology through its Polaris Safety Constellation Architecture. This unique architecture utilizes multiple language models that review and cross-validate outputs to ensure maximum accuracy and reduce risk, an essential feature for AI systems deployed in healthcare environments.
Additional measures include routine output testing, ongoing human evaluation and escalation, and rigorous cross-validation procedures to ensure consistency between simulated testing and real-world deployment. To date, Hippocratic AI’s agents have conducted over 115 million patient interactions with zero reported safety issues.
The latest $126 million funding will accelerate Hippocratic AI’s expansion plans, aimed at deploying its AI agents in more healthcare organizations across the globe. With partnerships already spanning over 50 health systems, payers, and pharmaceutical firms in six countries, including Cleveland Clinic, Northwestern Medicine, Moffitt Cancer Center, University Hospitals, and the UK’s Guy’s & St Thomas’ NHS Trust, the company is poised for continued growth.
The company plans to invest heavily in product innovation and pursue mergers and acquisitions to broaden its capabilities. Its CEO, Munjal Shah, emphasized the company’s patient-first philosophy: “This capital allows us to touch more lives while staying true to our core values of do no harm and patients first.”
Hippocratic AI’s valuation shows the broader surge in healthcare AI, a sector drawing high levels of venture capital amid growing demand for automation and operational efficiencies. Global venture funding rose 38% year-over-year in Q3 2025, with AI companies capturing nearly half of all funding.
Generative AI’s ability to improve patient communication, streamline administrative tasks, and enhance chronic disease management positions Hippocratic AI in a high-growth niche critical for the future of healthcare delivery.
Despite the promising outlook, the company faces challenges common to healthcare AI ventures. These include navigating complex regulatory landscapes worldwide, ensuring data privacy and security, and convincing healthcare providers to adopt new AI workflows without disrupting care standards. The necessity to maintain rigorous safety standards makes scaling more complex but also crucial for long-term success.
